Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acute Myeloid Leukemia Minimal Residual Disease Detection: The Difference from Normal Approach.

Current protocols in cytometry - 1 Jun 2020

Wood Brent L

Abstract excerpt

The identification of residual leukemia following therapy, termed minimal or measurable residual disease (MRD), has emerged as one of the most important prognostic factors for patients with acute leukemia, including acute myeloid leukemia (AML). Flow cytometry is a preferred method for MRD detection due to its general applicability and the rapid results that it makes available. In this article, the basic protocol...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Neoplasm
Share to Cell Survival
Share to Hematopoietic Stem Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Leukocyte Common Antigens

Share to Neoplasm, Residual

Share to Nucleophosmin

Share to Staining and Labeling

Source

Identifiers

PMID: 32311834
DOI: 10.1002/cpcy.73

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acute Myeloid Leukemia Minimal Residual Disease Detection: The Difference from Normal Approach.PMID 32311834Read ↗

Minimal residual disease in acute myelogenous leukemia.Semantic proximity Read ↗

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.Semantic proximity Read ↗

Minimal residual disease in acute myeloid leukemia: coming of age.Semantic proximity Read ↗

Prognostic Implication of Early Minimal Residual Disease Evaluation in Patients with Chronic Myelomonocytic LeukemiaSemantic proximity Read ↗

Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management.Semantic proximity Read ↗

MRD in Acute Leukemias: Lessons Learned from Acute Promyelocytic LeukemiaSemantic proximity Read ↗

Minimal Residual Disease Detection in Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Measurable residual disease testing in acute myeloid leukemia: current state, foundational models, and tools for future development.Semantic proximity Read ↗

Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Disease–Directed TherapySemantic proximity Read ↗

Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid LeukemiaSemantic proximity Read ↗

Minimal residual disease: optimal methods, timing, and clinical relevance for an individual patientSemantic proximity Read ↗

Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for “prime time”?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.